3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
9
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
HER2-negative Breast Cancer
1
Gastric Adenocarcinoma
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
58
Cisplatin
41
Capecitabine
27
Oxaliplatin
25
durvalumab
16
Fluorouracil
16
Leucovorin
15
S 1 (combination)
11
lenvatinib
10
Nivolumab
10
Irinotecan
10
pembrolizumab
8
apatinib
8
Immune Checkpoint Inhibitors
7
130-nm albumin-bound paclitaxel
7
tremelimumab
6
Bevacizumab
6
camrelizumab
5
Trastuzumab
5
Drug Therapy
5
Blood Specimen Collection
5
Albumin-Bound Paclitaxel
5
tislelizumab
4
irinotecan sucrosofate
4
Taxes
4
Liquid Biopsy
4
Folfox protocol
4
toripalimab
3
surufatinib
3
gemcitabine-oxaliplatin regimen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Biliary Tract Neoplasms
×
taxane
×
Clear all
NCT03668418
2018-09-12
xenoZ
University of Pisa
Unknown
120 enrolled